NCI Research Specialist (Clinician Scientist) Award

摘要 博士Karyn Goodman在Tisch癌症研究所（TCI）的癌症临床试验项目中发挥着关键作用， 支持国家癌症研究所资助的临床试验她对这项工作表现出了长期的承诺 通过她之前在大学担任临床研究副主任（AD）3年的角色， 科罗拉多癌症中心。在TCI的同一角色中，古德曼博士能够进一步扩展 她在科罗拉多所做的工作，并集中在五个主要目标：1）扩大获得临床 西奈山卫生系统（MSHS）的试验; 2）增加NCI赞助的试验数量 在MSHS中进行; 3）满足对临床试验进行更多监督和整合的需求 整个MSHS提供的服务; 4）支持初级教师开发演示者发起的试验 （IIT），并向实验治疗临床试验网络（ETCTN）提出概念， 支持;和，5）增加少数招募TCI临床试验。在制度上，她一直是 多项国家临床试验网络（NCTN）研究的当地PI，这些研究针对多个国家临床研究机构指定的癌症 中心，目前是一项ECOG/ACRIN试验和一项ETCTN试验的Mount Sinai PI，并担任 早期药物开发机会计划（EDDOP）在西奈山的PI。此外，她在 作为NCTN的国家领导人，她通过参与联盟的GI委员会， 肿瘤学和NRG肿瘤学的临床试验，以及她作为NCI联合主席的角色 胃肠道指导委员会。她很好地弥合了她在全国范围内所做的工作， 临床研究职位的机构AD。她带来了她在临床试验开发方面的专业知识， 她作为CALGB/Alliance 80803的国家研究主席获得了监督，这是一项II期试验， 评估了食管癌的PET导向治疗，国家放射肿瘤学负责人 RTOG/NRG 0848的研究者，这是一项研究佐剂作用的大型III期试验 可切除胰腺癌的放化疗。作为TCI的高级领导者，她的首要目标是 支持IIT和NCI资助的合作组临床试验的发展， 推进与癌症的斗争。R50资助机制无疑将有助于培养她的能力， 在西奈山医院扩大NCI资助的肿瘤学临床研究，并扩大这些试验的可及性 穿过MSHS。古德曼是唯一定位为这个奖项与她的机构和 国家服务中心致力于发展和支持癌症临床研究。

ABSTRACT Dr. Karyn Goodman plays a critical role in Tisch Cancer Institute’s (TCI) cancer clinical trial program and in supporting NCI-funded clinical trials. She has demonstrated a long-term commitment to this work through her previous role as Associate Director (AD) of Clinical Research for 3 years at the University of Colorado Cancer Center. In the same role in the TCI, Dr. Goodman has been able to further expand on the work she was doing in Colorado and has focused on five major goals: 1) to expand access to clinical trials across the Mount Sinai Health System (MSHS); 2) to increase the numbers of NCI-sponsored trials performed across the MSHS; 3) to address the need for more oversight and integration of clinical trial services provided across the MSHS; 4) to support junior faculty to develop investigator-initiated trials (IITs) and present concepts to the Experimental Therapeutic Clinical Trials Network (ETCTN) for potential support; and, 5) to increase minority recruitment to TCI clinical trials. Institutionally, she has been the local PI of numerous National Clinical Trials Network (NCTN) studies at several NCI-designated cancer centers and is currently the Mount Sinai PI for one ECOG/ACRIN trial and one ETCTN trial and serves as the PI for the Early Drug Development Opportunity Program (EDDOP) at Mount Sinai. In addition, she is a national leader in the NCTN both through her involvement in the GI committees of the Alliance for Clinical Trials in Oncology and the NRG Oncology, as well as her role as the co-chair of the NCI Gastrointestinal Steering Committee. She has nicely bridged the work she has done nationally with her institutional AD of Clinical Research position. She brings her expertise in clinical trial development and oversight which she gained as the National Study Chair of the CALGB/Alliance 80803, a Phase II trial that evaluated PET-directed therapy for esophageal cancer, and the National Radiation Oncology Principal Investigator of the RTOG/NRG 0848, a large Phase III trial investigating the role of adjuvant chemoradiation in resectable pancreas cancer. Her overarching goal as a senior leader in the TCI is to support the development of both IITs and NCI-funded cooperative group clinical trials that will further advance the fight against cancer. The R50 funding mechanism will undoubtedly help foster her ability to expand NCI-funded oncology clinical research at Mount Sinai Hospital and expand access to these trials across the MSHS. Dr. Goodman is uniquely positioned for this award with both her institutional and national service focused on developing and supporting cancer clinical research.